05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Fruit juices; non-alcoholic carbonated beverages; vegetable juices; whey beverages Bandages for dressings; breast-nursing pads; dietary supplements for animals; nutritional supplements; vitamin preparations; amino acids for medical purposes; medicinal drinks; eyepatches for medical purposes; food for babies; gauze for dressings; lacteal flour for babies; menstruation bandages; menstruation tampons; pharmaceutical preparations consisting of crude medicines for improvement of weak constitution; reagent paper for medical purposes; sanitary napkins; sanitary panties
2.
PRODUCTION METHOD FOR RARE FATTY ACID USING NOVEL ENZYME, AND NOVEL RARE FATTY ACID
ClostridiumClostridium, by using a fatty acid as a substrate. The present invention also provides a novel useful rare fatty acid that is obtained by these production methods.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
The present invention provides a combination of: (1) a composition containing a living bacterium of Bacteroides vulgatus isolated from nature; and (2) a composition containing a living bacterium of Bacteroides dorei isolated from nature.
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
05 - Pharmaceutical, veterinary and sanitary products
32 - Beers; non-alcoholic beverages
Goods & Services
Bandages for dressings; breast-nursing pads; dietary
supplements for animals; nutritional supplements; vitamin
preparations; amino acids for medical purposes; medicinal
drinks; eyepatches for medical purposes; food for babies;
gauze for dressings; lacteal flour for babies; menstruation
bandages; menstruation tampons; pharmaceutical preparations
consisting of crude medicines for improvement of weak
constitution; reagent paper for medical purposes; sanitary
napkins; sanitary panties. Fruit juices; non-alcoholic carbonated beverages; vegetable
juices; whey beverages.
5.
METHOD FOR PREDICTING ALLERGIC DISEASE USING MICRORNA
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japan)
NITTO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kunisawa, Jun
Yonejima, Yasunori
Abstract
Provided are a method for predicting the onset risk of an allergic disease in an infant fed with breast milk collected from a mother within 3 months after delivery, said method comprising measuring the amount of at least one miRNA selected from the group consisting of hsa-miR-200c-3p, hsa-miR-4286, hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-miR-30d-5p, hsa-miR-22-3p, hsa-miR-2392 and hsa-miR-6765-3p in the aforesaid breast milk, etc.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
05 - Pharmaceutical, veterinary and sanitary products
32 - Beers; non-alcoholic beverages
Goods & Services
Bandages for dressings; breast-nursing pads; dietary supplements for animals; nutritional supplements; vitamin preparations; amino acids for medical purposes; medicinal drinks; eyepatches for medical purposes; food for babies; gauze for dressings; lacteal flour for babies; menstruation bandages; menstruation tampons; pharmaceutical preparations consisting of crude medicines for improvement of weak constitution; reagent paper for medical purposes; sanitary napkins; sanitary panties Fruit juices; non-alcoholic carbonated beverages; vegetable juices; whey beverages
7.
HYDROXYLATED FATTY ACID HOMOPOLYMER AND PRODUCTION METHOD THEREOF
Provided are a hydroxylated fatty acid derivative, which contains a large amount of a hydroxylated fatty acid and is easy to intake and handle, and a production method of the same. Also provided is a production method of a hydroxylated fatty acid homopolymer, said method comprising polymerizing a hydroxylated fatty acid using an enzyme. The hydroxylated fatty acid homopolymer is stabilized. Also provided is a valuable novel hydroxylated fatty acid homopolymer which is obtained by the aforesaid production method.
Provided are: a composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway through futalosine or a futalosine derivative, said composition comprising as an active ingredient a fatty acid which carries 18 carbon atoms and has a hydroxyl group at the 10-position; and a composition for preventing or treating a disease which is caused by a bacterium having a menaquinone synthesis pathway through futalosine or a futalosine derivative.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY (Japan)
NITTO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Shinkura, Reiko
Yamamoto, Kota
Abstract
The present invention provides a pharmaceutical composition used for the treatment or prevention of allergic diseases. More specifically, the present invention provides a pharmaceutical composition for the treatment or prevention of allergic diseases, that includes a substance that induces selective IgA class switching of B cells. A PKC activator can be used as the substance that induces selective IgA class switching of B cells. The composition including the substance that induces selective IgA class switching of B cells can be useful as a mucosal adjuvant.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention provides lactobacillus-containing chocolate and a manufacturing method therefor, wherein the lactobacillus-containing chocolate contains live lactobacillus, and the average particle size of solid particles in said lactobacillus-containing chocolate is greater than 1 μm and less than 9 μm.
The present invention provides: a composition for preventing or treating metabolism disorders, the composition comprising Leuconostoc mesenteroides-producing exopolysaccharide; a composition for amplifying the amount of short-chain fatty acids in the intestines; a composition for reducing the ratio of bacteria belonging to the phylum Firmicutes to bacteria belonging to the phylum Bacteroidetes in the intestines; and a food product, pharmaceutical product, feed, and the like comprising the compositions.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
05 - Pharmaceutical, veterinary and sanitary products
32 - Beers; non-alcoholic beverages
Goods & Services
Absorbent cotton; adhesive plasters; bandages for dressings;
breast-nursing pads; dietary supplements for animals;
nutritional supplements; vitamin preparations; amino acids
for medical purposes; medicinal drinks; dietetic beverages
adapted for medical purposes; dietetic food adapted for
medical purposes; eyepatches for medical purposes; food for
babies; gauze for dressings; lacteal flour for babies;
menstruation bandages; menstruation tampons; pharmaceutical
preparations; reagent paper for medical purposes; sanitary
napkins; sanitary panties. Fruit juices; non-alcoholic beverages; vegetable juices
[beverage]; whey beverages.
13.
EMULSION COMPOSITION FOR PREVENTING OR AMELIORATING SNORING
The present invention provides an emulsion composition for preventing or ameliorating snoring, said emulsion composition including (A) a vegetable oil, (B) a sugar alcohol having 4 or more carbon atoms, and (C) an emulsifying agent, with the optional additional inclusion of (D) a vegetable essential oil. The emulsion composition exhibits superior emulsion stability, minimizes the separation of constituents during storage, does not require a homogenization operation at the time of use, can be conveniently used on the pharynx, and can be continuously ingested or used.
The present invention provides: a novel HYA derivative that has excellent physiological functions inherent to HYA and allows easy intake and handling; and a use thereof. The present invention relates to: a triglyceride or optical isomer thereof being characterized in that at least one fatty acid that forms an ester bond with a glycerol hydroxyl group is 10-hydroxy-cis-12-octadecenoic acid; and a composition (edible oil/fat, food, medicine, cosmetic etc.) containing said triglyceride or optical isomer thereof.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
A23D 9/007 - Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
By adding a viable lactic acid bacterium to a fat or oil composition, the present invention has succeeded in manufacturing a lactic acid bacterium-containing fat or oil composition that has a high viability and excellent resistance of the lactic acid bacterium. By adding a lactic acid bacterium powder or a chocolate with a high lactic acid bacterium concentration to a chocolate dough after tempering and before shaping, moreover, the present invention has succeded in manufacturing a lactic acid bacterium-containing chocolate containing a viable lactic acid bacterium by a simple manufacturing method. Thus, provided is a lactic acid bacterium-containing chocolate with high palatability that contains a viable lactic acid bacterium.
Provided are: a novel HYA derivative that has excellent physiological functions inherent to HYA and allows easy intake and handling; and a use thereof. The present invention relates to: a 10-hydroxy-cis-12-octadecenoic acid alkyl ester or optical isomer thereof, or an ester of 10-hydroxy-cis-12-octadecenoic acid and a divalent alkanol or an optical isomer of said ester; and a composition (edible oil/fat, food, medicine, cosmetic etc.) that contains said esters or optical isomers thereof.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
A23D 9/007 - Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
32 - Beers; non-alcoholic beverages
Goods & Services
Pharmaceutical preparations; dietary supplements for humans;
cotton swabs for medical use. Pacifiers for babies to be used during sleep; pacifiers for
babies; ice bag pillows [for medical purposes]; triangular
bandages; supportive bandages; surgical catguts; feeding
cups [for medical purposes]; dropping pipettes [for medical
purposes]; teats; medical ice bags; medical ice bag holders;
baby bottles; nursing bottles; finger guards [for medical
purposes]; ear plugs for sleeping; ear plugs for
soundproofing; anti-snoring device; medical apparatus and
instruments. Syrups for beverages; carbonated drinks [refreshing
beverages]; fruit juices; vegetable juices [beverage].
18.
NOVEL LACTIC ACID BACTERIUM AND COMPOSITION INCLUDING SAID LACTIC ACID BACTERIUM
The present invention provides a lactic acid bacterium for ameliorating lifestyle-related diseases such as hyperuricemia and fatty liver, and a composition that includes said lactic acid bacterium.
The present invention provides: the production of a hydroxylated fatty acid by a hydration reaction using a novel enzyme which is derived from a lactic acid bacterium and of which the substrate is a fatty acid; and a method for producing an oxo fatty acid by an enzymatic reaction or a chemical oxidation reaction in which the hydroxylated fatty acid serves as a substrate. The present invention also provide a novel rare fatty acid which is produced by one of the above-mentioned methods and has a utility value.
C07C 51/373 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in doubly bound form
C07C 59/185 - Saturated compounds having only one carboxyl group and containing keto groups
C07C 59/76 - Unsaturated compounds containing keto groups
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
Provided are: a metabolism-improving agent that comprises a rare fatty acid such as a hydroxylated fatty acid or an oxo fatty acid; and a food, a drug, etc., comprising the aforesaid metabolism-improving agent.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention provides an anti-inflammatory agent containing a rare fatty acid such as a hydroxylated fatty acid or an oxo fatty acid, and further provides foods, pharmaceuticals, and the like, containing said anti-inflammatory agent.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Provided are an exopolysaccharide produced by a novel lactic acid bacterium having IgA production-promoting capability, a method for producing the exopolysaccharide, and a composition and the like containing the exopolysaccharide.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
Provided is a calcium agent that is easily ingested and has superior flavor, disintegration properties in the mouth, and the like. The calcium agent has superior flavor, disintegration properties in the mouth, and the like by means of adding a disintegration agent and/or an organic acid or the like to a calcium salt and a magnesium salt.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Provided are an intestinal tract-protecting agent and an agent for preventing or ameliorating a disease caused by an injury in the barrier function of the intestinal tract, which comprise a hydroxylated fatty acid, in particular a hydroxylated unsaturated fatty acid, having hydroxyl group(s) at the 10- and/or 12-positions, said hydroxylated fatty acid being an intermediate in unsaturated fatty acid metabolism by a lactic acid bacterium.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A23K 1/16 - supplemented with accessory food factors; Salt blocks
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
C07C 59/42 - Unsaturated compounds containing hydroxy or O-metal groups
The present invention provides: Leuconostoc mesenteroides strain NTM048 deposited under accession number NITE BP-1519, or a variant strain or a processed bacterial product thereof; a lactic acid bacterium preparation including said strain or the processed bacterial product thereof; and an immunostimulation agent (in particular, an intestinal immunostimulation agent).
Provided is a composition that comprises bifidobacteria together with silicone and an antacid so that antacid properties can be imparted to the bifidobacteria, the stability in the stomach can be improved and the number of surviving bifidobacteria in the stomach can be increased.
The present invention provides: a metabolism-improving agent comprising a C-18 oxofatty acid having a carbonyl group at position-10 or position-12 and/or a C-18 hydroxyfatty acid having a hydroxy group at position-10 and/or position-12; and the use of the metabolism-improving agent as a food, a medicine or the like.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A23K 1/16 - supplemented with accessory food factors; Salt blocks
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention provides a method for producing an oxo fatty acid and a rare fatty acid, such as a conjugated fatty acid, a hydroxylated fatty acid, or a partially saturated fatty acid, using four types of enzymes (fatty acid hydratase, hydroxylated fatty acid dehydrogenase, oxo fatty acid isomerase, and oxo fatty acid enone reductase) derived from, for instance, a lactobacillus such as Lactobacillus plantarum. The present invention further provides a method for the more efficient production of an oxo fatty acid and the like by the partial combined use of chemical oxidation.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
